Fol. Biol. 2004, 50, 120-130
https://doi.org/10.14712/fb2004050030120
Interleukin-2 Therapy of Cancer
References
1. , W. F. (1992) Human gene therapy. Science 256, 808-813.
<https://doi.org/10.1126/science.256.5058.808>
2. , M. B. (2002) Interleukin-2: clinical applications. Semin. Oncol. 29, 12-17.
<https://doi.org/10.1053/sonc.2002.33077>
3. J., Neuber, K., Kamanabrou, D., Fluck, M., Brˆcker, E. B., Neumann, C., R¸nger, T. M., Schuler, G., von den Driesch, P., M¸ller, I., Paul, E., Patzelt, T., Reitz, M. (2002a) Combination chemotherapy with or without s.c. IL-2 anf IFN-α: results of a prospectively randomized trial of the Cooperative Advanced Malignant Melanoma Chemoimmunotherapy Group (ACIMM). Br. J. Cancer 86, 179-187.
<https://doi.org/10.1038/sj.bjc.6600043>
4. , J., Hoffmann, R., Franzke, M., Stief, C., Wandert, T., Reitz, M. (2002b) Thirteen-year, long-term efficacy of interferon alpha and interleukin 2-based home therapy in patients with advanced renal cell carcinoma. Cancer 95, 1045-1050.
<https://doi.org/10.1002/cncr.10783>
5. , J., Kirchner, H., Hanninen, E. L., Korfer, A., Fenner, M., Menzel, T., Deckert, M., Franzke, A., Jonas, U., Poliwoda, H. (1993) European studies of interleukin-2 in metastatic renal cell carcinoma. Semin. Oncol. 20, 22-26.
6. , L. T., Steerenberg, P. A., Koppenhagen, F. J., Kremer, B. H., De Mulder, P. H., Claessen, A. M., Scheper, R. J., Den Otter, W. (1994) PEG-IL-2 therapy of advanced cancer in the guinea pig. Impact of the primary tumor and beneficial effect of cyclophosphamide. Int. J. Cancer 58, 871-876.
<https://doi.org/10.1002/ijc.2910580621>
7. , M. H., Sznol, M., Atkins, M. B., Ciobanu, N., Micetich K. C., Boldt, D. H., Margolin, K. A., Aronson, F. R., Rayner, A. A., Hawkins, M. J., et al. (1990) Metastatic malignant melanoma treated with combined bolus and continuous infusion interleukin-2 and lymphokine-activated killer cells. J. Clin. Oncol. 8, 1138-1147.
<https://doi.org/10.1200/JCO.1990.8.7.1138>
8. , A., Pierce, W., Sayah, D., deKernion, J., Wallach, D., Aderka, D., Figlin, R. A. (1993) Soluble tumor necrosis factor receptor expression in patients with metastatic renal cell carcinoma treated with interleukin-2-based immunotherapy. J. Immunother. 13, 175-180.
<https://doi.org/10.1097/00002371-199304000-00004>
9. , J. (1989) Local immunotherapy of cancer with interleukin 2. Immunol. Lett. 21, 267-273.
<https://doi.org/10.1016/0165-2478(89)90018-7>
10. , J. (1990) Local and regional immunotherapy of cancer with interleukin 2 (Review). J. Cancer Res. Clin. Oncol. 116, 1-7.
<https://doi.org/10.1007/BF01612631>
11. , J. (1993a) IL-2 gene therapy of cancer: at its beginning. Folia Biol. (Praha) 39, 279-288.
12. , J. (1993b) IL-2 and gene therapy of cancer (Review). Int. J. Oncol. 2, 1049-1052.
13. Bubeník, J. (1994) Utilization of IL 2 and IL 2 gene transfer for regional immunotherapy of cancer. In: CytokineInduced Tumour Immunogenicity: From Exogenous Molecules to Gene Therapy, eds. Forni, G., Foa, R., Santoni, A., Frati, L., pp. 113-130, Academic Press, London, U. K.
14. , J. (1996a) Cytokine gene-modified vaccines in the therapy of cancer. Pharmacol. Ther. 69, 1-14.
<https://doi.org/10.1016/0163-7258(95)02016-0>
15. , J. (1996b) Gene transfer for immunotherapy of cancer (Editorial). Gene Ther. 3, 944-945.
16. , J. (2003) MHC class I downregulation and tumour immunotherapy (Review). Oncol. Rep. 10, 2005-2008.
17. , J., Perlmann, P., Indrová, M., Šímová, J., Jandlová, T., Neuwirt, J. (1983) Growth inhibition of an MC-induced mouse sarcoma by TCGF (IL-2)-containing preparations. Cancer Immunol. Immunother. 14, 205-206.
<https://doi.org/10.1007/BF00205362>
18. , J., Indrová, M., Perlmann, P., Berzins, K., Mach, O., Kraml, J., Toulcová, A. (1985) Tumour-inhibitory effects of TCGF (IL-2)-containing preparations. Cancer Immunol. Immunother. 19, 57-61.
<https://doi.org/10.1007/BF00199313>
19. , J., Kieler, J., Indrová, M. (1986) Local treatment with human recombinant interleukin 2 inhibits growth of MC-induced sarcomas in syngeneic mice. Folia Biol. (Praha) 32, 209-211.
20. , J., Voitenok, N. N., Kieler, J., Prassolov, V. S., Chumakov, P. M., Bubeníková, D., Šímová, J., Jandlová, T. (1988) Local administration of cells containing an inserted IL-2 gene and producing IL-2 inhibits growth of human tumours in nu/nu mice. Immunol. Lett. 19, 279-282.
<https://doi.org/10.1016/0165-2478(88)90155-1>
21. , J., Šímová, J., Jandlová, T. (1990) Immunotherapy of cancer using local administration of lymphoid cells transformed by IL-2 cDNA and constitutively producing IL-2. Immunol. Lett. 23, 287-292.
<https://doi.org/10.1016/0165-2478(90)90074-Z>
22. , J., Šímová, J., Bubeníková, D. (1992) Interleukin 2 and cancer. Folia Biol. (Praha) 38, 155-169.
23. , J., Šímová, J., Bubeníková, D., Zeuthen, J., Indrová, M. (1995a) Interleukin-2 gene therapy of residual EL-4 leukaemia potentiates the effect of cyclophosphamide pretreatment. J. Cancer Res. Clin. Oncol. 121, 39-43.
<https://doi.org/10.1007/BF01202727>
24. , J., Bubeníková, D., Šímová, J., Lotzová, E. (1995b) Interleukin 2 (IL-2) and gene therapy of cancer: treatment of myeloid leukaemia with irradiated genetically modified IL-2-producing cell vaccine. J. Exp. Clin. Cancer Res. 14, 83-86.
25. , J., Šímová, J., Hájková, R., Sobota, V., Jandlová, T., Šmahel, M., Sobotková, E., Vonka, V. (1999) Interleukin 2 gene therapy of residual disease in mice carrying tumours induced by HPV 16. Int. J. Oncol. 14, 593-597.
26. , J., Den Otter, W., Huland, E., (2000) Local cytokine therapy of cancer: interleukin-2, interferons and related cytokines. Cancer Immunol. Immunother. 49, 116-122.
27. , J., Mikyšková, R., Vonka, V., Mendoza, L., Šímová, J., Šmahel, M., Indrová, M. (2003) Interleukin-2 and dendritic cells as adjuvants for surgical therapy of tumours associated with human papillomavirus type 16. Vaccine 21, 891-896.
<https://doi.org/10.1016/S0264-410X(02)00537-6>
28. , J., Sleijfer, D. T., van der Graaf, W. T., de Vries, E. G., Willemse, P. H., Mulder, N. H. (1993) A progress report on the outpatient treatment of patients with advanced renal cell carcinoma using subcutaneous recombinant interleukin-2. Semin. Oncol. 20, 16-21.
29. , E., Rosenberg, S. A. (2001) Patients with melanoma metastases at cutaneous and subcutaneous sites are highly susceptible to interleukin-2-based therapy. J. Immunother. 24, 88-90.
<https://doi.org/10.1097/00002371-200101000-00010>
30. , J., Bannerji, R., Saito, S., Heston, W., Fair, W., Gilboa, E. (1993) Regression of bladder tumors in mice treated with interleukin 2 gene-modified tumor cells. J. Exp. Med. 177, 1127-1134.
<https://doi.org/10.1084/jem.177.4.1127>
31. , G., De Stefani, A., Giovarelli, M., Barioglio, M.G., Cavallo, G. P., Jemma, C., Forni, G. (1988) Treatment of recurrent squamous cell carcinoma of the head and neck with low doses of interleukin-2 injected perilymphatically. Cancer 62, 2482-2485.
<https://doi.org/10.1002/1097-0142(19881215)62:12<2482::AID-CNCR2820621205>3.0.CO;2-9>
32. G. C., Batchelor, D., Kersten, M. J., Vyth-Dreese, F. A., Sein, J., van de Kasteele, W. F., Nooijen, W. J., Nieweg, O. E., de Waal, M. A., Boogerd, W. (2003) Temozolomide followed by combined immunotherapy with GM-CSF, low-dose IL2 and IFN alpha in patients with metastatic melanoma. Br. J. Cancer 88, 175-180.
<https://doi.org/10.1038/sj.bjc.6600717>
33. , J., Schwartzentruber, M. D. (2001) High-dose interleukin-2 is an intensive treatment regardless of the venue of administration. Cancer J. 6, 103-104.
34. , J. P., Creekmore, S., Weiss, G. R., Margolin, K., Markowitz, A. B., Roper, M., Parkinson, D., Ciobanu, N., Fisher, R. I., Boldt, D. H. (1989 ) A phase II study of interleukin-2 and lymphokine-activated killer cells in patients with metastatic malignant melanoma. J. Clin. Oncol. 7, 477-485.
<https://doi.org/10.1200/JCO.1989.7.4.477>
35. , J. P., Gaynor, E. R., Boldt, D. H., Doroshow, J. H., Bar, M. H., Sznol, M., Mier, J., Sparano, J., Fisher, R. I., Weiss, G. (1991) A phase II study of high-dose continuous infusion interleukin-2 with lymphokine-activated killer cells in patients with metastatic melanoma. J. Clin. Oncol. 9, 6416-6418.
<https://doi.org/10.1200/JCO.1991.9.4.641>
36. , J. A., Sella, A., Amato, R. J., Tu, S. M., Millikan, R. E., Finn, L. D., Banks, M., Logothetis, C. J. (1997) Phase II trial of 5-fluorouracil, interferon-alpha and continuous infusion interleukin-2 for patients with metastatic renal cell carcinoma. Cancer 80, 2128-2132.
<https://doi.org/10.1002/(SICI)1097-0142(19971201)80:11<2128::AID-CNCR12>3.0.CO;2-0>
37. , A. H., Nashan, D., Rubben, A., Knop, J. (2000) High dose inhalation interleukin-2 therapy for lung metastases in patients with malignant melanoma. Cancer 88, 2042-2046.
<https://doi.org/10.1002/(SICI)1097-0142(20000501)88:9<2042::AID-CNCR9>3.0.CO;2-J>
38. , E. R., Pardoll, D. M., Itaya, T., Golumbek, P., Levitsky, H. I., Simons, J. W., Karasuyama, H., Vogelstein, B., Frost, P. (1990) Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 60, 397-403.
<https://doi.org/10.1016/0092-8674(90)90591-2>
39. , R., Guarini, A., Gansbacher, B. (1992) IL-2 treatment for cancer: from biology to gene therapy. Br. J. Cancer 66, 992-998.
<https://doi.org/10.1038/bjc.1992.400>
40. , G., Cavallo, G. P., Giovarelli, M., Benetton, G., Jemma, C., Barioglio, M. G., De Stefani, A., Forni, M., Santoni, A., Modesti, A. (1988) Tumor immunotherapy by local injection of interleukin 2 and non-reactive lymphocytes. Experimental and clinical results. Prog. Exp. Tumor Res. 32, 187-212.
<https://doi.org/10.1159/000414679>
41. , G., Fisher, R. I., Rosenberg, S. A., Sznol, M., Parkinson, D. R., Louie, A. C. (1995) Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J. Clin. Oncol. 13, 688-696.
<https://doi.org/10.1200/JCO.1995.13.3.688>
42. , G. A., Fisher, R. I., Rosenberg, S. A., Sznol, M., Parkinson, D. R., Louie, A. C. (1996) Long-term response data for 255 patients with metastatic renal cell carcinoma treated with high-dose recombinant interleukin-2 therapy. J. Clin. Oncol. 14, 2410-2411.
<https://doi.org/10.1200/JCO.1996.14.8.2410>
43. , B., Zier, K., Daniels, B., Cronin, K., Bannerji, R., Gilboa, E. (1990) Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp. Med. 172, 1217-1224.
<https://doi.org/10.1084/jem.172.4.1217>
44. , E., Rubinov, R., Gaitini, D., Meretyk, S., Best, L. A., Native, O., Stein, A., Erlich, N., Beny, A., Zidan, J., Haim, N., Kuten, A. (2002) Interleukin-2, interferon-alpha, 5-fluorouracil, and vinblastine in the treatment of metastatic renal cell carcinoma: a prospective phase II study: the experience of Rambam and Lin Medical Centers 19962000. Cancer 95, 1644-1649.
<https://doi.org/10.1002/cncr.10842>
45. , S., Smith, K. (1977) Long term culture of tumour-specific cytotoxic T cells. Nature 268, 154-156.
<https://doi.org/10.1038/268154a0>
46. , B. J., Hoffman, D. M., Moldawer, N., Belldegrun, A., Figlin, R. A. (2001) Treatment of metastatic renal cell intensive care unit: an analysis of 124 consecutively treated patients. Cancer J. 7, 112-121.
47. , E. A., Mazumeder, A., Zhang, H. Z., Rosenberg, S. A. (1982) Lymphokine activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J. Exp. Med. 155, 1823-1841.
<https://doi.org/10.1084/jem.155.6.1823>
48. , S., Naruo, K., Ootsu, K., Houkan, T., Shiho, O., Tsukamoto, K. (1987) Suppression of pulmonary tumour metastasis in mice by recombinant human interleukin-2: role of asialo GM1-positive cells. Immunology 60, 173-179.
49. , G., Langer, W., Theiss, M., Gruss, A., Frohmuller, H. G. (1996) Immunochemotherapy for metastatic renal cell carcinoma using a regimen of interleukin-2, interferon-alpha and 5-fluorouracil. J. Urol. 156, 18-21.
<https://doi.org/10.1016/S0022-5347(01)65926-3>
50. , E., Huland, H. (1989) Local continuous high dose interleukin 2: a new therapeutic model for the treatment of advanced bladder carcinoma. Cancer Res. 49, 5469-5474.
51. , E., Huland, H., Heinzer, H. (1992) Interleukin-2 by inhalation: local therapy for metastatic renal cell carcinoma. J. Urol. 147, 344-348.
<https://doi.org/10.1016/S0022-5347(17)37233-6>
52. , E., Heinzer, H., Mir, T. S., Huland, H. (1997) Inhaled interleukin-2 therapy in pulmonary metastatic renal cell carcinoma. Cancer J. Sci. Am. 3 (Suppl. 1) S98-S105.
53. , E., Heinzer, H., Huland, H., Yung, R. (2000) Overview of interleukin-2 inhalation therapy. Cancer J. Sci. Am. 6 (Suppl. 1) S104-S112.
54. , M., Bubeník, J., Jakoubková, J., Sobota, V., Helmichová, E., Šímová, J. (1995) IFNα therapy of renal cell carcinoma: defect of lymphocyte sensitivity to mitogenic and activating cytokine signals in patients nonresponding to therapy. Int. J. Oncol. 7, 523-526.
55. , M., Bubeník, J., Mikyšková, R., Vonka, V., Šmahel, M., Žák, R., Šímová, J., Bieblová, J., Mendoza, L., Jandlová, T. (2002) Tumour-inhibitory and antimetastatic effects of IL-2 in mice carrying MHC class Itumours of HPV16 origin. Int. J. Oncol. 20, 643-646.
56. , M., Bubeník, J., Mikyšková, R., Mendoza, L., Šimová, J., Bieblová, J., Jandlová, T., Jinoch, P., Šmahel, M., Vonka, V., Pajtasz-Piasecka, E. (2003) Chemoimmunotherapy in mice carrying HPV16-associated, MHC class I+ and class Itumours: Effects of CBM-4A potentiated with IL-2, IL-12, GM-CSF and genetically modified tumour vaccines. Int. J. Oncol. 22, 691-695.
57. , J. K., Banks, R. E., Forbes, M. A., Hallam, S., Jenkins, A., Patel, P. M., Hall, G. D., Velikova, G., Adams, J., Crossley, A., Johnson, P. W., Whicher, J. T., Selby, P. J. (1996) A phase II study of interferon-alpha, interleukin-2 and 5-fluorouracil in advanced renal carcinoma: clinical data and laboratory evidence of protease activation. Br. J. Urol. 77, 638-649.
<https://doi.org/10.1046/j.1464-410X.1996.09573.x>
58. , H., Tohyama, N., Tada, T. (1989) Autocrine growth and tumorigenicity of interleukin 2-dependent helper T cells transfected with IL-2 gene. J. Exp. Med. 169, 13-25.
<https://doi.org/10.1084/jem.169.1.13>
59. Kedar, E., Chriqui-Zeira, E., Lebendiker, Z. (1985) In: Immunity to Cancer, eds. Reif, A. E., Mitchell, M. S., pp. 537. Academic Press, New York.
60. , E., Ben-Aziz, R., Epstein, E., Leshem, B. (1989) Chemo-immunotherapy of murine tumors using interleukin-2 (IL-2) and cyclophosphamide. IL-2 can facilitate or inhibit tumor growth depending on the sequence of treatment and the tumor type. Cancer Immunol. Immunother. 29, 74-78.
<https://doi.org/10.1007/BF00199920>
61. , U., Eggermont, A. M. (2000) The emerging role of cytokines in the treatment of advanced melanoma. For the EORTC Melanoma Cooperative Group. Oncology 58, 89-95.
<https://doi.org/10.1159/000012085>
62. , H., Yamashita, A., Tadakuma, T., Sakaguchi, S. (1991) Inhibition of growth of rat hepatoma by local injection of liposomes containing recombinant interleukin-2. Antitumor effect of IL-2 liposome. Biotherapy 3, 211-218.
<https://doi.org/10.1007/BF02171684>
63. , R., Rosenberg, S. A. (1985) Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin 2. Cancer Res. 45, 3735-3741.
64. , V., Langlade-Demoyen, P., Kourilsky, P., LarssonSciard, E. L. (1991) Interleukin 2-dependent activation of tumor-specific cytotoxic T lymphocytes in vivo. Eur. J. Immunol. 21, 851-854.
<https://doi.org/10.1002/eji.1830210350>
65. , A., Hoffken, K., Schmidt, R. E., Diehl, V., Kloke, O., Gamm, H., Hayungs, J., Oster, W., Bohm, M., Kolitz, J. E., Franks, C. R., Herrmann, F., Mertelsmann, R. (1989) A phase-II study of low-dose cyclophosphamide and recombinant human interleukin-2 in metastatic renal cell carcinoma and malignant melanoma. Cancer Immunol. Immunother. 28, 275-281.
<https://doi.org/10.1007/BF00205237>
66. , P., Bordin, V., Vaghi, M., Fumagalli, L., Bordoni, A., Mengo, S., Bucovec, R., Fumagalli, E., Malugani, F., Ardizzoia, A., Giani, L., Gardani, G. S., Tancini, G. (2002) Ten-year survival results in metastatic renal cell cancer patients treated with monoimmunotherapy with subcutaneous low-dose interleukin-2. Anticancer Res. 22, 1061-1064.
67. , C. M., Suzuki, Y., Chen, L. P., Okayasu, T., Calkins, C. E., Wheelock, E. F. (1990) Maintenance and cure of the L5178Y murine tumor-dormant state by interleukin 2: in vivo and in vitro effects. Cancer Res. 50, 1361-1367.
68. , R. A., Van Weering, D. H., Dullens, H. F., Den Otter, W. (1991) Intratumoral low-dose interleukin-2 induces rejection of distant solid tumour. Cancer Immunol. Immunother. 33, 389-394.
<https://doi.org/10.1007/BF01741599>
69. , R., Matsumoto, M., Kitagawa, T., Harada, M., Sato, K. (1986) Effect of recombinant interleukin 2 (R-IL2) on in vivo growth of murine myeloma X5563. Cancer Immunol. Immunother. 23, 25-30.
<https://doi.org/10.1007/BF00205551>
70. , K. A. (2000) Interleukin-2 in the treatment of renal cancer. Semin. Oncol. 27, 194-203.
71. , V., De Mulder, P. H., Schornagel, J. H., Verweij, J., Van den Broek, P., Galazka, A., Roy, S., Ruiter, D. J. (1991) Clinical and immunopathological results of a phase II study of perilymphatically injected recombinant interleukin-2 in locally far advanced, nonpretreated head and neck squamous cell carcinoma. J. Immunother. 10, 63-68.
<https://doi.org/10.1097/00002371-199102000-00009>
72. , R., Bubeník, J., Mendoza, L., Vonka, V., Šmahel, M., Šímová, J., Jandlová, T. (2001) Local cytokine treatment of HPV16-associated tumours results in inhibition of their lung metastases. Clin. Exp. Metastasis 18, 581-587.
<https://doi.org/10.1023/A:1011987206008>
73. , R., Indrová, M., Šímová, J., Jandlová, T., Bieblová, J., Jinoch, P., Bubeník, J., Vonka, V. (2004) Treatment of minimal residual disease after surgery or chemotherapy in mice carrying HPV16-associated tumours: Cytokine and gene therapy with IL-2 and GM-CSF. Int. J. Oncol. 24, 161-167.
74. , D. A., Ruscetti, F. W., Gallo, R. (1976) Selective in vitro growth of T-lymphocytes from normal human bone marrow. Science 193, 1007-1008.
<https://doi.org/10.1126/science.181845>
75. , R. J., Mazumdar, M., Bacik, J., Russo, P., Berg, W. J., Metz, E. M. (2000) Effect of cytokine therapy on survival for patients with advanced renal cell carcinoma. J. Clin. Oncol. 18, 1928-1935.
<https://doi.org/10.1200/JCO.2000.18.9.1928>
76. , P., Forni, G., Lollini, P. L. (1999) Cytokine gene therapy: hopes and pitfalls. Ann. Oncol. 10, 261-266.
<https://doi.org/10.1023/A:1008304721889>
77. , S., Escudier, B., Lasset, C., Douillard, J. Y., Savary, J., Chevreau, C., Ravaud, A., Mercatello, A., Peny, J., Mousseau, M., Philip, T., Tursz, T. (1998) Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais díImmunotherapie. N. Engl. J. Med. 338, 1272-1278.
<https://doi.org/10.1056/NEJM199804303381805>
78. , S., Caty, A., Lesimple, T., Douillard, J. Y., Escudier, B., Rossi, J. F., Viens, P., Gomez, F. (2000) Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil. Groupe Francais dëImmunotherapie, Federation Nationale des Centres de Lutte Contre le Cancer. J. Clin. Oncol. 18, 4009-4015.
<https://doi.org/10.1200/JCO.2000.18.24.4009>
79. , S., Schiphorst, P. P., Weijl, N. I., Dijkstra, N., Van Wees, A., Brouwenstein, N., Vaessen, N., Van Krieken, J. H., Hermans, J., Cleton, F. J., Schrier, P. I. (2000) Vaccination of melanoma patients with an allogeneic, genetically modified interleukin 2-producing melanoma cell line. Hum. Gene Ther. 11, 739-735.
<https://doi.org/10.1089/10430340050015635>
80. , W. W., Theoret, M. R., Restifo, N. P. (2000) The future of interleukin-2: enhancing therapeutic anticancer vaccines. Cancer J. Sci. Am. 6 (Suppl. 1) S76-S80.
81. , D. R., Abrams, J. S., Wiernik, P. H., Rayner, A. A., Margolin, K. A., Van Echo, D. A., Sznol, M., Dutcher, J. P., Aronson, F. R., Doroshow, J. H. (1990) Interleukin-2 therapy in patients with metastatic malignant melanoma: a phase II study. J. Clin. Oncol. 8, 1650-1656.
<https://doi.org/10.1200/JCO.1990.8.10.1650>
82. , G., Severini, G., Menniti, D., De Vinci, C., Corrado, F. (1984) Tumour regression after intralesional injection of interleukin 2 (IL-2) in bladder cancer. Preliminary report. Int. J. Cancer 34, 359-367.
<https://doi.org/10.1002/ijc.2910340312>
83. , G., De Vinci, C., Lo Conte, G. E., Aiello, E., Fornarola, V., Bergami, T., Busutti, L., Boriani, S., Palareti, A., Capanna, R., Maver, P., Dragoni, E. (2001) Immunotherapy of metastatic kidney cancer. Int. J. Cancer 94, 109-120.
<https://doi.org/10.1002/ijc.1426>
84. , G., De Vinci, C., Lo Conte, G., Mazzuca, A., Corrado, G., Menniti, D., Benati, A., Romagnoli, P., Fornarola, V., Busutti, L., Palareti, A., Capanna, R., Di Maio, V., Ratini, S., Gulino, A., Vacca, A., Melchiorri, L., Ferrari, M., Boriani, S., Baricordi, R. O. (2003) Allogeneic gene-modified tumour cells in metastatic kidney cancer. Preliminary report. Folia Biol. (Praha) 49, 147-159.
85. , A., Tzehoval, E., Katz, A., Vadai, E, Revel, M., Feldman, M., Eisenbach, L. (1992) Interleukin 6 gene transfection into Lewis lung carcinoma tumour cells suppresses the malignant phenotype and confers immunotherapeutic competence against parental metastatic cells. Cancer Res. 52, 3679-3686.
86. , P., Caroli, U. M., Bauer, J., Paul, T., Schlegel, C., Eigentler, T. K., Weide, B., Schwarz, M., Garbe, C. (2003) Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases. Br. J. Cancer 89, 1620-1626.
<https://doi.org/10.1038/sj.bjc.6601320>
87. , L., Gambacorti-Passerini, C., Squadrelli-Saraceno, M., Grosso, M. I., Cantu, G., Molinari, R., Orazi, A., Parmiani, G. (1990) In vivo interleukin 2-induced activation of lymphokine-activated killer cells and tumor cytotoxic T-cells in cervical lymph nodes of patients with head and neck tumors. Cancer Res. 50, 5551-5557.
88. , S. A. (1988) Immunotherapy of cancer using interleukin 2: current status and future prospects. Immunol Today 9, 58-62.
<https://doi.org/10.1016/0167-5699(88)91261-3>
89. , S. A., Mulé, J. J., Spiess, P. J., Reichert, C. M., Schwarz, S. L. (1985a) Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. J. Exp. Med. 161, 1169-1188.
<https://doi.org/10.1084/jem.161.5.1169>
90. , S. A., Lotze, M. T., Muul, L. M., Leitman, S., Chang, A. E., Ettinghauser, S. E., Matory, Y. L., Skibber, J. M., Shiloni, E., Vetto, J. T., Seipp, C. A., Simpson, C., Reichert, C. M. (1985b) Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N. Engl. J. Med. 313, 1485-1492.
<https://doi.org/10.1056/NEJM198512053132327>
91. , S. A., Lotze, M. T., Muul, L. M., Chang, A. E., Avis, F. P., Leitman, S., Linehan, W. M., Robertson, C. N., Lee, R. E., Rubin, J. T., Seip, C. A., Simpson, C. G., White, D. E. (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N. Engl. J. Med. 316, 889-897.
<https://doi.org/10.1056/NEJM198704093161501>
92. , S. A., Lotze, M. T., Yang, J. C., Linehan, W. M., Seipp, C., Calabro, S., Karp, S. E., Sherry, R. M., Steinberg, S., White, D. E. (1989) Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer. J. Clin. Oncol. 7, 1863-1874.
<https://doi.org/10.1200/JCO.1989.7.12.1863>
93. , S. A., Yang, J. C., Topalian, S. L., Schwartzentruber, D. J., Weber, J. S., Parkinson, D. R., Seipp, C. A., Einhorn, J. H., White, D. E. (1994a) Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 271, 907-913.
<https://doi.org/10.1001/jama.1994.03510360033032>
94. , S. A., Yannelli, J. R., Yang, J. C., Topalian, S. L., Schwartzentruber, D. J., Weber, J. S., Parkinson, D. R., Seipp, C. A., Einhorn, J. H., White, D. E. (1994b) Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J. Natl. Cancer Inst. 86, 1159-1166.
<https://doi.org/10.1093/jnci/86.15.1159>
95. , J. A., Cristiano, R. J. (1997) Gene therapy for cancer: what have we done and where are we going? J. Natl. Cancer Inst. 89, 21-39.
<https://doi.org/10.1093/jnci/89.1.21>
96. , V. P., Klein, W. R., De Jong, W. A., Misdorp, W., Den Otter, W., Steerenberg, P. A., De Jong, W. H., Ruitenberg, E. J. (1989) Local interleukin-2 therapy in bovine ocular squamous cell carcinoma. A pilot study. Cancer Immunol. Immunother. 30, 165-169.
<https://doi.org/10.1007/BF01669425>
97. , I. G., Finke, S., Trojaneck, B., Denkena, A., Lefterova, P., Schwella, N., Heuft, H. G., Prange, G., Korte, M., Takeya, M., Dorbic, T., Neubauer, A., Wittig, B., Huhn, D. (1999) Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma. Br. J. Cancer 81, 1009-1016.
<https://doi.org/10.1038/sj.bjc.6690800>
98. , D. J. (2001) High-dose interleukin-2 is an intensive treatment regardless of the venue of administration. Cancer J. 7, 103-104.
99. , S., Schaefer, A. E. (1986) Successful immunotherapy of mouse melanoma and sarcoma with recombinant interleukin-2 and cyclophosphamide. J. Biol. Response Mod. 5, 411-422.
100. , V., Bubeník, J., Indrová, M., Vlk, V., Jakoubková, J. (1997) Use of cryopreserved lymphocytes for assessment of the immunological effects of interferon therapy in renal cell carcinoma patients. J. Immunol. Methods 203, 1-10.
<https://doi.org/10.1016/S0022-1759(97)00020-3>
101. , J. A., Kohler, P. C., Hank, J. A., Moore, K. H., Bechhofer, R., Storer, B., Sondel, P. M. (1988) Repetitive weekly cycles of interleukin-2. II. Clinical and immunologic effects of dose, schedule, and addition of indomethacin. J. Natl. Cancer Inst. 80, 1451-1461.
<https://doi.org/10.1093/jnci/80.18.1451>
102. , M., Rivoltini, L., Cantu, G., Ravagnani, F., Parmiani, G., Molinari, R. (1990) Local adoptive immunotherapy of advanced head and neck tumors with LAK cells and interleukin-2. Tumori 76, 566-571.
<https://doi.org/10.1177/030089169007600611>
103. , J., Bubeník, J., Jandlová, T., Indrová, M. (1998) Irradiated IL-2 gene-modified plasmacytoma vaccines are more efficient than live vaccines. Int. J. Oncol. 12, 1195-1198.
104. , J., Reiniö, M., Sobota, V., »apkov·, J., Bubeník, J., Jandlová, T. (2000) Irradiation of genetically modified plasmocytoma vaccines results in upregulation of the CD80/IL-2 gene expression and higher therapeutic efficacy of the vaccines. Folia Biol. (Praha) 46, 11-16.
105. , J. A., Peace, D. J., Klarnet, J. P., Kern, D. E., Greenberg, P. D., Cheever, M. A. (1986) Eradication of disseminated murine leukemia by treatment with highdose interleukin 2. J. Immunol. 137, 3675-3680.
<https://doi.org/10.4049/jimmunol.137.11.3675>
106. , L. (1993) Gene therapy. Healy approves an unproven treatment. Science 259, 172.
<https://doi.org/10.1126/science.8421780>
107. , J. (1987) Local and systemic effects during interleukin-2 therapy of mouse mammary tumors. Cancer Res. 47, 4296-4298.
108. , J. (1988) Local interleukin 2 therapy of mouse mammary tumors of various immunogenicities. Cancer Res. 48, 2193-2197.
109. , J., Pauly, J. L., Harlos, J. P. (1987) Influence of the administration schedule on the therapeutic effect of interleukin-2. Int. J. Cancer 39, 530-533.
<https://doi.org/10.1002/ijc.2910390421>
110. , C. M., De Mulder, P. H. (2000) Locoregional immunotherapy in cancer patients: review of clinical studies. Ann. Oncol. 11, 1229-1239.
<https://doi.org/10.1023/A:1008335318764>
111. , J., Rosenthal, F. M., Bannerji, R., Heston, W. D., Fair, W. R., Gansbacher, B., Gilboa, E. (1994) Immunotherapy of prostate cancer in the Dunning rat model: use of cytokine gene modified tumor vaccines. Cancer Res. 54, 1760-1765.
112. , V., Rössner, P., Indrová, M., Bubeník, J., Sobota, V. (1998) Interleukin 2 gene therapy of surgical minimal residual tumour disease. Int. J. Cancer 76, 115-119.
<https://doi.org/10.1002/(SICI)1097-0215(19980330)76:1<115::AID-IJC18>3.0.CO;2-B>
113. , W. H., Tauer, K. W., Yannelli, J. R., Marshall, G. D., Orr, D. W., Thurman, G. B., Oldham, R. K. (1987) Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N. Engl. J. Med. 316, 898-905.
<https://doi.org/10.1056/NEJM198704093161502>
114. , T. L., Letessier, E., Hirabayashi, H., Vitolo, D., Bryant, J., Barnes, L., Snyderman, C., Johnson, J. T., Myers, E., Herberman, R. B. (1993) Evidence for local and systemic activation of immune cells by peritumoral injections of interleukin 2 in patients with advanced squamous cell carcinoma of the head and neck. Cancer Res. 53, 5654-5662.
115. , J. C. Rosenberg, S. A. (1997) An ongoing prospective randomized comparison of interleukin-2 regimens for the treatment of metastatic renal cell cancer. J. Sci. Am. 3 (Suppl. 1) S79-S84.
116. , K., Mivazaki, K., Nagashima, A., Ishida, T., Kuda, T., Yano, T., Sugimachi, K., Nomoto, K. (1987) Induction of lymphokine-activated killer cells by intrapleural instillations of recombinant interleukin-2 in patients with malignant pleurisy due to lung cancer. Cancer Res. 47, 2184-2187.
117. , S., Tanaka, R., Takai, N., Ono, K. (1988) Local administration of autologous lymphokine-activated killer cells and recombinant interleukin 2 to patients with malignant brain tumors. Cancer Res. 48, 5011-5016.
